Pharmaceutical company Genzyme, whose European therapeutics business is based in Cowley, launched a new treatment for kidney disease patients.
Genzyme said a team of 30 Oxford employees was directly involved in working on the new product, called Renvela.
Elevated serum phosphorus levels are common in patients with advanced kidney disease and the new treatment is designed to control this.
Steve Higgins, interim general manager at Genzyme, Oxford, said: “At Oxford, we are proud of the part we play in delivering highly effective therapies for patients with life-threatening conditions such as chronic kidney disease.
“The launch of Renvela in the UK marks an important step in helping to improve the management of chronic kidney disease, and could make a real difference to the lives of patients living with the condition.”
The active ingredient for Renvela (sevelamer carbonate) will be manufactured at Genzyme’s UK manufacturing site at Haverhill, Suffolk, which will supply the global market.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereComments are closed on this article